RxDoctor Payments Data

Andrew Kim

Pain Medicine · Las Vegas, NVNPI 1417100918

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 97.7% of the total across 406 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 54 manufacturers reported payments, led by Boston Scientific at 32.7% of the total. Reporting peaked in 2019 at $2,448 and has fallen 60.0% since, to $978 in 2025.

$10,996in general payments, 2019–2025

Across 406 payments — averaging $27.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$4K
  • Medtronic$991
  • Scilex Pharmaceuticals Inc.$706
  • Biotronik NRO, Inc.$475
  • Vertos Medical, Inc.$452
  • Flowonix Medical Incorporated$426
  • plus $4K from 48 others
$58,203in research payments, 2019–2025

Across 10 payments — averaging $5820.31 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Anika Therapeutics, Inc.$50K
  • AbbVie$8K
  • Medtronic$230

What the payments were for

  • Travel & lodging$2502%
  • Food & beverage$10,74298%
  • Education$40%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$10,996 in reported general payments places this provider in the 80th percentile of 101 pain medicine providers in Nevada.

See all pain medicine providers in Nevada

Medicare billing

Part B allowed, 2024
$461,156
Medicare patients
830
Services billed
21,147

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen182$4,039
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen116$3,504
Morphine Sulfate ErMorphine Sulfate29$2,405
Lidocaine17$2,260
Celecoxib42$1,679
Oxycodone Hcl73$1,474
Gabapentin109$756
Tramadol Hcl94$723
Acetaminophen-CodeineAcetaminophen With Codeine41$543
Pregabalin35$413
Hydromorphone Hcl12$310
Baclofen41$234
Tizanidine Hcl30$201
Lorazepam12$156
Zolpidem Tartrate13$150

Paid to pharmacies, not to this prescriber.

Other pain medicine in Las Vegas

See the full list for Nevada

Where these figures come from

Is this you, or does something look wrong? →